Keyword Analysis & Research: agenus
Keyword Research: People who searched agenus also searched
Search Results related to agenus on Search Engine
-
Better immunotherapies | Agenus
https://agenusbio.com/
WebAgenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through subsidiary MiNK Therapeutics ), adjuvants and vaccines (through subsidiary ...
DA: 90 PA: 46 MOZ Rank: 24
-
Agenus Inc. (AGEN) Stock Price, News, Quote & History - Yahoo Finance
https://finance.yahoo.com/quote/AGEN
WebAgenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript Reported EPS is $-0.13 EPS, expectations were $-0.053. AGEN isn’t one of the 30 most popular stocks among …
DA: 50 PA: 92 MOZ Rank: 12
-
Pipeline | Agenus
https://agenusbio.com/pipeline/
WebPipeline | Agenus. We are a clinical-stage immunotherapy company targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents. Product Candidate. Target. Partner. Phase 1. Phase 2. Majority / Fully-owned pipeline. Botensilimab +/- Balstilimab.
DA: 19 PA: 97 MOZ Rank: 14
-
Agenus - Wikipedia
https://en.wikipedia.org/wiki/Agenus
WebAgenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants desugned for use with various vaccines.
DA: 71 PA: 7 MOZ Rank: 87
-
Our History | Agenus
https://agenusbio.com/about-us/our-history/
WebAgenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes.
DA: 36 PA: 24 MOZ Rank: 79
-
Team | Agenus
https://agenusbio.com/about-us/team/
WebWe have brought together top talent and expertise to advance our mission, building a team of over 400 employees across our offices in the US and Europe. View our open positions. With an innovative business model and bold scientific minds, we aim to develop the next generation of immunotherapies and make them available to every waiting patient.
DA: 86 PA: 96 MOZ Rank: 100
-
Agenus Inc. - Investor Relations
https://investor.agenusbio.com/overview/default.aspx
WebMar 5, 2024 · Agenus is an immuno-oncology company focused on the discovery and development of potentially revolutionary new treatments that leverage the body’s immune system to fight cancer and infectious diseases. presentation. Latest Press Releases. March 14, 2024. Agenus Reports Fourth Quarter and Full Year 2023 Results. March 6, 2024.
DA: 54 PA: 68 MOZ Rank: 28
-
Agenus Inc. - Agenus Completes Enrollment in Randomized …
https://investor.agenusbio.com/news/news-details/2023/Agenus-Completes-Enrollment-in-Randomized-Phase-2-Clinical-Trial-of-BotensilimabBalstilimab-in-Advanced-Colorectal-Cancer/default.aspx
WebOctober 10, 2023. Download. LEXINGTON, Mass.-- (BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in ACTIVATE-Colorectal, a randomized Phase 2 trial in advanced colorectal cancer (CRC) evaluating …
DA: 74 PA: 46 MOZ Rank: 14
-
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination …
https://investor.agenusbio.com/news/news-details/2023/ESMO-2023-Agenus-BotensilimabBalstilimab-Combination-Delivers-Durable-Responses-across-Multiple-Sarcoma-Subtypes/default.aspx
WebOct 21, 2023 · Download. LEXINGTON, Mass.-- (BUSINESS WIRE)-- Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company’s phase 1b study of botensilimab (BOT, multifunctional immune activator) in combination with balstilimab …
DA: 28 PA: 3 MOZ Rank: 14
-
Agenus | LinkedIn
https://www.linkedin.com/company/agenus
WebAgenus | LinkedIn. Biotechnology Research. Lexington, Massachusetts 32,138 followers. See jobs Follow. View all 295 employees. Overview. Jobs. Life. About us. Agenus is a leading...
DA: 55 PA: 43 MOZ Rank: 9